Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,891.00-0.93%ETH$1,878.67-0.53%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
AR

NASDAQ · ARAV

Aravive, Inc.

Healthcare · Biotechnology

$0.04

Down-$0.01 (-13.39%)

Updated Aug 14, 2026, 10:07 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.95M
P/E ratio
-0.02
Dividend yield
0.00%
52-week range
— – —
Volume
4.04M
Avg. volume
2.16M

Price performance

ARAV price history

1M range · 0 trading sessions · Daily adjusted prices

ARAV does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ARAV news

The latest Smart Investors Daily articles mentioning ARAV.

Stock researchCompany · Overview

ARAV research

Overview

Company profile and research snapshot.

Company profile

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$0.25
Implied upside
—
Analysts
6
ARAV recent ratings
DateFirmRatingTarget
Aug 22, 2023Cantor FitzgeraldNeutral—
Aug 3, 2023William BlairMarket Perform—
Aug 3, 2023HC Wainwright & Co.Neutral—
Aug 3, 2023EF HuttonHold—
Aug 3, 2023BTIGNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Jan 18, 2024

Nasdaq Jumps Over 100 Points; US Jobless Claims Fall To 187,000

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded down 0.33% to 37,143.30 while the NASDAQ rose 0.97% to 15,000.30. The S&P 500 also rose, gaining, 0.43% to 4,759.68. Check This Out: Alphabet, Electronic Arts And 2 Other Stocks Insiders Are Selling   Leading and Lagging Sectors   Information technology shares rose by 1.4% on Thursday. In trading on Thursday, health care shares dipped by 0.9%.   Top Headline   U.S. initial jobless claims fell by 16,000 to 187,000 in the week ending January 18, compared to market estimates of 207,000.   Equities Trading UP   Agrify Corporation (NASDAQ: AGFY) shares shot up 133% to $2.75. Agrify said it entered into first Hydrocarbon Extraction Lab & Vertical Farming unit facility in California. Shares of Lytus Technologies Holdings PTV. Ltd. (NASDAQ: LYT) got a boost, surging 114% to $0.2032 after falling 5% on Wednesday. Celularity Inc. (NASDAQ: CELU) shares were also up, gaining 59% to $0.3013 ...

GlobeNewswire Inc. · Jan 17, 2024

Aravive, Inc. to Delist from The Nasdaq Stock Market

HOUSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market (“Nasdaq”)  and, based upon ownership of its shares by fewer than 300 holders of record, deregister its common stock under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and suspend its public reporting obligations.

PennyStocks · Aug 31, 2023

What Makes a Successful Penny Stocks Trader?

Use these tips to become a successful penny stocks trader The post What Makes a Successful Penny Stocks Trader? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By